Kaplan-Meier curve of OS for FAS population. Testing between the two treatment arms was carried out by log-rank test. In the anlotinib group and the TACE group, the 12-month OS rates were 96.3% and 97.2%, respectively (P=0.44). OS, overall survival; FAS, full analysis set; TACE, transcatheter arterial chemoembolization.